Lomitapide: A guide to its use in adults with homozygous familial hypercholesterolaemia in the EU

Drugs and Therapy Perspectives

Volumn 29, Issue 12, 2013, Pages 373-378

  Lyseng Willliamson, Katherine A ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LINOLEIC ACID; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; ROSUVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; APHERESIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; INTENTION TO TREAT ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; LOW FAT DIET; MAXIMUM PERMISSIBLE DOSE; MAXIMUM TOLERATED DOSE; PHASE 3 CLINICAL TRIAL (TOPIC); SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84890407239     PISSN: 11720360     EISSN: 11791977     Source Type: Journal    
DOI: 10.1007/s40267-013-0087-z     Document Type: Article

References (22)

1. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262-8.
2. National Cholesterol Education Programme. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): NIH Publication No. 02-5215. Bethesda: National Heart, Lung and Blood Institute, 2002.
3. Raper A, Kolansky DM, Cuchel M. Treatment of familial hypercholesterolemia: is there a need beyond statin therapy? Curr Atheroscler Rep. 2012;14(1):11-6.
4. Sjouke B, Kusters DM, Kastelein JJ, et al. Familial hypercholesterolemia: present and future management. Curr Cardiol Rep. 2011;13(6):527-36.
5. Ito MK, McGowan MP, Moriarty PM. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia. J Clin Lipidol. 2011;5:S38-45.
6. Thompson GR, HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198(2):247-55.
7. Raal FJ, Pilcher GJ, Illingworth DR, et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia. Atherosclerosis. 1997;135(2):249-56.
8. Raal FJ, Pappu AS, Illingworth DR, et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000;150(2):421-8.
9. Marais AD, Raal FJ, Stein EA, et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008;197(1):400-6.
10. Moorjani S, Roy M, Torres A, et al. Mutations of low-density-lipoprotein- receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet. 1993;341(8856):1303-6.
11. Lojuxta (lomitapide) 5, 10 and 20 mg hard capsules: summary of prescribing information. London: European Medicines Agency, 2013.
12. Juxtapid™ (lomitapide): US prescribing information. Cambridge, MA: Aegeron Pharmaceuticals, Inc., 2013.
13. Hussain MM, Rava P, Walsh M, et al. Multiple functions of microsomal triglyceride transfer protein. Nutr Metab (Lond). 2012;21(9):14.
14. Rizzo M, Wierzbicki AS. New lipid modulating drugs: the role of microsomal transport protein inhibitors. Curr Pharm Des. 2011;17(9):943-9.
15. Cuchel M, Rader DJ. Microsomal transfer protein inhibition in humans. Curr Opin Lipidol. 2013;24(3):246-50.
16. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40-6.
17. Rizzo M. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. Idrugs. 2010;13(2):103-11.
18. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356(2):148-56.
19. Cuchel M, Meagher E, du Toit Theron H, et al. Apheresis treatment does not affect the lipid-lowering efficacy of lomitapide, a microsomal triglyceride transfer protein inhibitor, in patients with homozygous familial hypercholesterolemia [abstract A17396]. Circulation. 2012;126:21 Suppl.
20. Grundy S, Davidson M, Bays H, et al. Prevalence and analysis of hepatic steatosis in patients with hypercholesterolemia who lack traditional risk factors associated with steatosis [abstract plus poster]. 60th Annual Meeting of the American Association for the Study of Liver Diseases; 30 Oct-3 Nov 2009; Boston, MA.
21. ClinicalTrials.gov. Long term, follow-on study of lomitapide in patients with homozygous familial hypercholesterolemia NCT00943306. 2013. http://clinicaltrials.gov/show/NCT00943306. Accessed 2 Oct 2013.
22. Perry CM. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs. 2013;13(4):285-96.